Canine coronavirus

Recent Developments in Therapies and Strategies Against COVID-19

Published in Hanadi Talal Ahmedah, Muhammad Riaz, Sagheer Ahmed, Marius Alexandru Moga, The Covid-19 Pandemic, 2023

Misbah Hameed, M. Zia-Ul-Haq, Marius Moga

A study to evaluate the use of NSAID in SARS-CoV also looked at indomethacin. The results of the study suggested that indomethacin showed good in vitro antiviral activity against canine coronavirus, inhibiting virus replication and provide protection to the host cell from damage induced by virus, this antiviral activity was also noticed in vivo and also against human SARS-CoV at a dose of 1 mg/kg [58].

Indomethacin: an exploratory study of antiviral mechanism and host-pathogen interaction in COVID-19

View Article

Journal Information

Published in Expert Review of Anti-infective Therapy, 2022

Nishant Shekhar, Harpinder Kaur, Phulen Sarma, Ajay Prakash, Bikash Medhi

In vivo efficacy of indomethacin was ascertained by assessing the time of recovery in dogs infected with canine-CoV in a study conducted by Xu et al. (2020). Significantly rapid improvement was observed in infected dogs treated symptomatically and with indomethacin (1 mg/kg) as compared to symptomatic treatment and ribavirin, however, there was no significant difference from that with symptomatic treatment + canine hemoglobin + anti-canine coronavirus serum + canine blood immunoglobulin + interferon treatments [17,18].

Canine coronavirus

Explore chapters and articles related to this topic

Recent Developments in Therapies and Strategies Against COVID-19

Indomethacin: an exploratory study of antiviral mechanism and host-pathogen interaction in COVID-19